163 related articles for article (PubMed ID: 23458532)
1. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease?
Tursi A
Aliment Pharmacol Ther; 2013 Apr; 37(7):752. PubMed ID: 23458532
[No Abstract] [Full Text] [Related]
2. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.
Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S
Aliment Pharmacol Ther; 2013 Apr; 37(7):752-3. PubMed ID: 23458531
[No Abstract] [Full Text] [Related]
3. [Adalimumab vasculitis in a patient with Crohn's disease].
Muñoz Villafranca C; Izu Belloso RM; Bravo Rodriguez MT; Basterra Olabarrieta S
Gastroenterol Hepatol; 2013 Apr; 36(4):296-7. PubMed ID: 23522950
[No Abstract] [Full Text] [Related]
4. Commentary: IBD combination therapy - adalimumab plus immunosuppressants.
Andrews JM
Aliment Pharmacol Ther; 2013 Jan; 37(1):156. PubMed ID: 23205476
[No Abstract] [Full Text] [Related]
5. Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease.
Taxonera C; Mendoza JL; Ortega L; Pérez MI; Díaz-Rubio M
J Crohns Colitis; 2012 May; 6(4):488-91. PubMed ID: 22398051
[TBL] [Abstract][Full Text] [Related]
6. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
Lopez-Sanroman A; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
[No Abstract] [Full Text] [Related]
7. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
Tursi A; Elisei W; Picchio M; Penna A
Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
[No Abstract] [Full Text] [Related]
8. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
9. Biological therapy for Crohn's disease in a liver transplant patient.
Bendezú García RA; Rodríguez Manrique MA; Hernández Martínez A; Lázaro Sáez M; Patrón Román GO; Amat Alcaraz S; Vega Sáenz JL
J Dig Dis; 2013 Oct; 14(10):564-6. PubMed ID: 23437819
[No Abstract] [Full Text] [Related]
10. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
Barthel HR; Gille T; Halbsguth A; Kramer M
J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
[No Abstract] [Full Text] [Related]
11. Clinically silent Crohn's disease in a patient with Takayasu's arteritis unresponsive to conventional therapies.
Yilmaz N; Can M; Alibaz-Oner F; Direskeneli H
Rheumatol Int; 2013 Dec; 33(12):3091-3. PubMed ID: 23143554
[TBL] [Abstract][Full Text] [Related]
12. Commentary: infliximab or adalimumab in Crohn's disease?
Sprakes MB; Hamlin PJ
Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
[No Abstract] [Full Text] [Related]
13. Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
McDonnell MJ; Rutherford RM; O'Regan A
J Crohns Colitis; 2014 Sep; 8(9):1140-1. PubMed ID: 24631310
[No Abstract] [Full Text] [Related]
14. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
[No Abstract] [Full Text] [Related]
15. Listeria monocytogenes infection in Crohn's disease treated with adalimumab.
Willson KJ; Jacob A; Shetti MP; Bhatia R; Yee K; Osler W
Med J Aust; 2012 Oct; 197(8):466-7. PubMed ID: 23072245
[No Abstract] [Full Text] [Related]
16. [Efficacy and safety of Adalimumab in Crohn's disease].
Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary carcinoid tumor in a patient on adalimumab for Crohn's disease.
Betteridge JD; Veerappan GR
Inflamm Bowel Dis; 2013 Feb; 19(2):E29-30. PubMed ID: 22447376
[No Abstract] [Full Text] [Related]
18. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment.
Lie MR; Peppelenbosch MP; West RL; Zelinkova Z; van der Woude CJ
Aliment Pharmacol Ther; 2014 Nov; 40(10):1202-8. PubMed ID: 25263077
[TBL] [Abstract][Full Text] [Related]
20. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
Nancey S; Boschetti G; Cotte E; Cathey-Javouhay A; Laidet M; Chichery A; Francois Y; Glehen O; Flourié B
Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289
[No Abstract] [Full Text] [Related]
[Next] [New Search]